KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) Debt to Equity (2016 - 2025)

NovoCure's Debt to Equity history spans 11 years, with the latest figure at $0.57 for Q4 2025.

  • For Q4 2025, Debt to Equity rose 112.07% year-over-year to $0.57; the TTM value through Dec 2025 reached $0.57, up 112.07%, while the annual FY2025 figure was $0.57, 112.07% up from the prior year.
  • Debt to Equity for Q4 2025 was $0.57 at NovoCure, roughly flat from $0.57 in the prior quarter.
  • Across five years, Debt to Equity topped out at $1.59 in Q1 2024 and bottomed at $0.27 in Q2 2024.
  • The 5-year median for Debt to Equity is $1.28 (2022), against an average of $1.0.
  • The largest annual shift saw Debt to Equity surged 152.77% in 2021 before it tumbled 83.02% in 2025.
  • A 5-year view of Debt to Equity shows it stood at $1.37 in 2021, then fell by 6.41% to $1.28 in 2022, then grew by 12.55% to $1.44 in 2023, then plummeted by 81.27% to $0.27 in 2024, then skyrocketed by 112.07% to $0.57 in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Debt to Equity are $0.57 (Q4 2025), $0.57 (Q3 2025), and $0.28 (Q2 2025).